Understanding clinical risk decision making regarding development of depression during interferon-alpha treatment for hepatitis-C: A qualitative interview study

International Journal of Nursing Studies

Volumn 49, Issue 12, 2012, Pages 1480-1488

  Hepgul, Nilay ^a   Kodate, Naonori ^b   Anderson, Janet E ^c   Henderson, Max ^a   Ranjith, Gopinath ^d   Hotopf, Matthew ^a   Pariante, Carmine M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Decision making; Depression; Hepatitis C; Interferon alpha; Nurse clinicians

Indexed keywords

ALPHA INTERFERON;

ARTICLE; CHEMICALLY INDUCED DISORDER; DECISION MAKING; DEPRESSION; HEPATITIS C; HUMAN; INTERVIEW; NURSING DISCIPLINE; RISK FACTOR; UNITED KINGDOM;

DECISION MAKING; DEPRESSION; HEPATITIS C; HUMANS; INTERFERON-ALPHA; INTERVIEWS AS TOPIC; LONDON; RISK FACTORS; SPECIALTIES, NURSING;

EID: 84869876911     PISSN: 00207489     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijnurstu.2012.07.016     Document Type: Article

References (48)

1. Ademmer K., Beutel M., Bretzel R., Clemens J., Reimer C. Suicidal ideation with IFN-alpha and ribavirin in a patient with hepatitis C. Psychosomatics 2001, 42(4):365-367.
2. Agarwal K., Cross T.J., Gore C. Chronic hepatitis C. British Medical Journal 2007, 334(7584):54-55.
3. Asnis G.M., De La Garza R. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. Journal of Clinical Gastroenterology 2006, 40(4):322-335.
4. Bowers J., Jorm A.F., Henderson S., Harris P. General practitioners' detection of depression and dementia in elderly patients. Medical Journal of Australia 1990, 153(4):192-196.
5. Bull S.J., Huezo-Diaz P., Binder E.B., Cubells J.F., Ranjith G., Maddock C., Miyazaki C., Alexander N., Hotopf M., Cleare A.J., Norris S., Cassidy E., Aitchison K.J., Miller A.H., Pariante C.M. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Molecular Psychiatry 2009, 14(12):1095-1104.
6. Carroll J.S., Johnson E.J. Decision Research: A Field Guide 1990, Sage, Newbury Park, CA.
7. Cooksey R. Judgement Analysis: Theory, Methods, and Applications 1996, Academic Press, San Diego, CA.
8. Currey J., Botti M. Naturalistic decision making: a model to overcome methodological challenges in the study of critical care nurses' decision making about patients' hemodynamic status. American Journal of Critical Care 2003, 12(3):206-211.
9. Dieperink E., Ho S.B., Tetrick L., Thuras P., Dua K., Willenbring M.L. Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. General Hospital Psychiatry 2004, 26(3):237-240.
10. Dieperink E., Ho S.B., Thuras P., Willenbring M.L. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003, 44(2):104-112.
11. Dixon-Woods M. Using framework-based synthesis for conducting reviews of qualitative studies. BMC Medicine 2011, 9:39.
12. Erim Y., Tagay S., Beckmann M., Bein S., Cicinnati V., Beckebaum S., Senf W., Schlaak J.F. Depression and protective factors of mental health in people with hepatitis C: a questionnaire survey. International Journal of Nursing Studies 2010, 47(3):342-349.
13. Evon D.M., Esserman D.A., Ramcharran D., Bonner J.E., Fried M.W. Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. Journal of Psychosomatic Research 2011, 71(5):349-356.
14. Farber G.A., Levin T., White C.A. A cognitive therapy conceptualization of panic disorder exacerbated by interferon treatment. General Hospital Psychiatry 2005, 27(5):329-337.
15. Fattovich G., Giustina G., Favarato S., Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. Journal of Hepatology 1996, 24(1):38-47.
16. Fontana R.J., Schwartz S.M., Gebremariam A., Lok A.S., Moyer C.A. Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C. Psychosomatics 2002, 43(5):378-385.
17. Franzen P.L., Buysse D.J., Rabinovitz M., Pollock B.G., Lotrich F.E. Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment. Psychiatry Research 2010, 177(1-2):240-245.
18. Fukunishi K., Tanaka H., Maruyama J., Takahashi H., Kitagishi H., Ueshima T., Maruyama K., Sakata I. Burns in a suicide attempt related to psychiatric side effects of interferon. Burns 1998, 24(6):581-583.
19. Galvao-de Almeida A., Guindalini C., Batista-Neves S., de Oliveira I.R., Miranda-Scippa A., Quarantini L.C. Can antidepressants prevent interferon-alpha-induced depression? A review of the literature. General Hospital Psychiatry 2010, 32(4):401-405.
20. Glacken M., Kernohan G., Coates V. Diagnosed with hepatitis C: a descriptive exploratory study. International Journal of Nursing Studies 2001, 38(1):107-116.
21. Guest G., Bunce A., Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods 2006, 18(1):59-82.
22. Hedberg B., Satterlund Larsson U. Observations, confirmations and strategies - useful tools in decision-making process for nurses in practice?. Journal of Clinical Nursing 2003, 12(2):215-222.
23. Hilsabeck R.C., Hassanein T.I., Perry W. Biopsychosocial predictors of fatigue in chronic hepatitis C. Journal of Psychosomatic Research 2005, 58(2):173-178.
24. Hoffman R., Millitello L. Cognitive Perspectives on Cognitive Task Analysis: Historical Origins and Modern Communities of Practice 2009, Taylor and Francis/CRC Press, Boca Raton, FL.
25. Holtzheimer P.E., Veitengruber J., Wang C.C., Krows M., Thiede H., Wald A., Roy-Byrne P. Utility of the Beck Depression Inventory to screen for and track depression in injection drug users seeking hepatitis C treatment. General Hospital Psychiatry 2010, 32(4):426-432.
26. Janssen H.L., Brouwer J.T., van der Mast R.C., Schalm S.W. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. Journal of Hepatology 1994, 21(2):241-243.
27. Klein G. Sources of Power: How People Make Decisions 1998, MIT Press, Cambridge, MA.
28. Knott A., Dieperink E., Willenbring M.L., Heit S., Durfee J.M., Wingert M., Johnson J.R., Thuras P., Ho S.B. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. American Journal of Gastroenterology 2006, 101(10):2254-2262.
29. Koskinas J., Merkouraki P., Manesis E., Hadziyannis S. Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. Digestive Diseases 2002, 20(3-4):284-288.
30. Lotrich F.E., Rabinovitz M., Gironda P., Pollock B.G. Depression following pegylated interferon-alpha: characteristics and vulnerability. Journal of Psychosomatic Research 2007, 63(2):131-135.
31. Morasco B.J., Rifai M.A., Loftis J.M., Indest D.W., Moles J.K., Hauser P. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. Journal of Affective Disorders 2007, 103(1-3):83-90.
32. Mosier K.L., Fischer U.M. Judgement and decision making by individuals and teams: issues, models, and applications. Reviews of Human Factors and Ergonomics 2010, 6:198-256.
33. Neri S., Bertino G., Petralia A., Giancarlo C., Rizzotto A., Calvagno G.S., Mauceri B., Abate G., Boemi P., Di Pino A., Ignaccolo L., Vadala G., Misseri M., Maiorca D., Mastrosimone G., Judica A., Palermo F. A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. Journal of Clinical Gastroenterology 2010, 44(9):e210-e217.
34. Pariante C.M., Landau S., Carpiniello B. Interferon alfa-induced adverse effects in patients with a psychiatric diagnosis. New England Journal of Medicine 2002, 347(2):148-149.
35. Patterson A.L., Morasco B.J., Fuller B.E., Indest D.W., Loftis J.M., Hauser P. Screening for depression in patients with hepatitis C using the Beck Depression Inventory-II: do somatic symptoms compromise validity?. General Hospital Psychiatry 2011, 33(4):354-362.
36. Pope C., Ziebland S., Mays N. Qualitative research in health care. Analysing qualitative data. British Medical Journal 2000, 320(7227):114-116.
37. Raison C.L., Demetrashvili M., Capuron L., Miller A.H. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005, 19(2):105-123.
38. Raison C.L., Woolwine B.J., Demetrashvili M.F., Borisov A.S., Weinreib R., Staab J.P., Zajecka J.M., Bruno C.J., Henderson M.A., Reinus J.F., Evans D.L., Asnis G.M., Miller A.H. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Alimentary Pharmacology and Therapeutics 2007, 25(10):1163-1174.
39. Ramsey S.E., Engler P.A., Stein M.D., Brown R.A., Cioe P., Kahler C.W., Promrat K., Rose J., Anthony J., Solomon D.A. Effect of CBT on depressive symptoms in methadone maintenance patients undergoing treatment for hepatitis C. Journal of Addiction Research & Therapy 2011, 2(2):2-10.
40. Ritchie J., Spencer L. Qualitative data analysis for applied policy research. Analyzing Qualitative Research 1994, 173-194. Routledge, London. A. Bryman, R.G. Burgess (Eds.).
41. Ritchie J., Spencer L., O'Connor W. Carrying out qualitative analysis. Qualitative Research Practice: A Guide for Social Science Students and Researchers 2003, 219-262. Sage, London. J. Ritchie, J. Lewis (Eds.).
42. Sockalingam S., Links P.S., Abbey S.E. Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update. Journal of Viral Hepatitis 2010, 18(3):153-160.
43. Stewart B.J., Mikocka-Walus A.A., Harley H., Andrews J.M. Help-seeking and coping with the psychosocial burden of chronic hepatitis C: a qualitative study of patient, hepatologist, and counsellor perspectives. International Journal of Nursing Studies 2011, 49(5):560-569.
44. Szabo E., Lotz G., Paska C., Kiss A., Schaff Z. Viral hepatitis: new data on hepatitis C infection. Pathology Oncology Research 2003, 9(4):215-221.
45. Weinrieb R.M., Auriacombe M., Lynch K.G., Chang K.M., Lewis J.D. A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients. Journal of Clinical Psychiatry 2003, 64(12):1502-1510.
46. Wichers M.C., Kenis G., Koek G.H., Robaeys G., Nicolson N.A., Maes M. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. Journal of Psychosomatic Research 2007, 62(2):207-214.
47. Xiao Y., Milgram P., Doyle D.J. Capturing and modeling planning expertise in anesthesiology: results of a field study. Naturalistic Decision Making Expertise: Research and Applications 1997, 197-205. Lawrence Erlbaum, Mahwah, NJ. C. Zsambok, G. Klein (Eds.).
48. Zsambok C.E. Naturalistic decision making research and improving team decision making. Naturalistic Decision Making Expertise: Research and Applications 1997, 111-120. Lawrence Erlbaum, Mahwah, NJ. C. Zsambok, G. Klein (Eds.).